SKK
EIGR

Shepherd Kaplan Krochuk’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-37
Closed -$175K – 562
2014
Q3 		$175K Buy
37
+3
+9% +$15.8K 0.02% 450
2014
Q2 		$246K Sell
34
-12
-26% -$60K 0.03% 404
2014
Q1 		$245K Buy
+46
New +$217K 0.03% 398

Other funds holding EIGR

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Shepherd Kaplan Krochuk's EIGR Position: Q4 2014 in Review

Shepherd Kaplan Krochuk sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2014, closing a stake of 37 shares — an estimated $175K sold.

Shepherd Kaplan Krochuk first reported a position in EIGR in Q1 2014 and held it in 3 quarters. The position peaked at $246K in Q2 2014. 66 funds tracked by Wall St. Rank hold EIGR as of Q4 2014.

  • Shepherd Kaplan Krochuk reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 37 Eiger BioPharmaceuticals, Inc. shares in Q4 2014, an estimated $175K.
  • Shepherd Kaplan Krochuk first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 3 quarters.
  • Shepherd Kaplan Krochuk's Eiger BioPharmaceuticals, Inc. position peaked at $246K in Q2 2014.
  • 66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2014.

Based on Shepherd Kaplan Krochuk's 13F filing for Q4 2014, filed 17 Feb 2015.